The increased GLO1 activity in human GLO1 transgenic rats results in lower levels of dicarbonyls and dicarbonyl‐derived AGEs in blood and tissues (Brouwers et al. 2011), and protects against diabetes‐induced endothelial dysfunction (Brouwers et al. 2010) and retinal pathology (Berner et al. 2012). The gene discussed is GLO1; the disease is endothelial dysfunction.